Oxford Biomedica Dirección

Dirección controles de criterios 1/4

El CEO de Oxford Biomedica's es Frank Mathias, nombrado en Mar 2023, tiene una permanencia de 1.08 años. posee directamente un 0.02% de las acciones de la empresa, con un valor de €50.97K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 3.8 años, respectivamente.

Información clave

Frank Mathias

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.2yrs
Participación del CEO	0.02%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Frank Mathias (61 yo)

1.2yrs

Permanencia

Dr. Frank Mathias is Chief Executive Officer and Director of Oxford Biomedica plc from March 27, 2023. Dr. Mathias was the Chief Executive Officer of Rentschler Biopharma SE from April 2016 until March 202...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stuart Paynter	CFO & Director	6.8yrs	UK£888.00k	0.019% £ 69.5k
Frank Mathias	CEO & Director	1.2yrs	sin datos	0.020% £ 74.3k
Thierry Cournez	COO & Oxford Site Head	less than a year	sin datos	sin datos
James Miskin	Chief Quality & Technical Officer	no data	sin datos	0.14% £ 528.0k
Matthew Treagus	Chief Information Officer	2.8yrs	sin datos	0.0097% £ 36.2k
Sophia Bolhassan	Head of Investor Relations	no data	sin datos	sin datos
Natalie Walter	General Counsel & Company Secretary	5yrs	sin datos	sin datos
Lisa James	Chief People Officer	2.1yrs	sin datos	sin datos
Kyriacos Mitrophanous	Chief Innovation Officer	less than a year	sin datos	sin datos
Kati Hudson	Head of Intellectual Property and Contracts	no data	sin datos	sin datos
Sebastien Ribault	Chief Commercial Officer	1.5yrs	sin datos	sin datos
Mark Caswell	Site Head of US Operations	less than a year	sin datos	sin datos

1.5yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de OXOA no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stuart Paynter	CFO & Director	6.8yrs	UK£888.00k	0.019% £ 69.5k
Frank Mathias	CEO & Director	1.2yrs	sin datos	0.020% £ 74.3k
Michael Hayden	Non-Independent Non-Executive Director	2.8yrs	UK£130.00k	0.040% £ 148.5k
Frederic Doliveux	Non-Executive Chair	3.9yrs	UK£1.16m	0.37% £ 1.4m
William Langston	Member of Scientific Advisory Board	no data	sin datos	sin datos
Peter Stern	Member of Scientific Advisory Board	no data	sin datos	sin datos
Krystof Bankiewicz	Member of Scientific Advisory Board	no data	sin datos	sin datos
Heather Preston	Independent Non-Executive Director	6.2yrs	UK£140.00k	0.018% £ 68.0k
Dame Davies	Senior Independent Director	3.2yrs	UK£65.00k	0.0010% £ 3.7k
Catherine Moukheibir	Independent Non-Executive Director	2.4yrs	UK£140.00k	0.026% £ 95.7k
Stuart Henderson	Independent Vice Chair	7.9yrs	UK£85.00k	0.011% £ 40.4k
Robert Ghenchev	Non-Executive Director	4.9yrs	sin datos	sin datos

3.9yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de OXOA se considera experimentada (3.8 años de antigüedad promedio).

Oxford Biomedica Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Oxford Biomedica plc Announces Board Changes

Non-Executive Chair recently bought €115k worth of stock

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

High number of new directors

Oxford Biomedica plc Announces Siyamak Rasty Will Not Be Standing for Re-Election

Recent updates

Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024

Full year 2023 earnings released: UK£1.63 loss per share (vs UK£0.41 loss in FY 2022)

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc to Report Fiscal Year 2023 Results on Apr 29, 2024

New minor risk - Shareholder dilution

Oxford Biomedica plc (LSE:OXB) completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH.

Oxford Biomedica plc Provides Business Update

Oxford Biomedica plc (LSE:OXB) entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for €15 million.

New major risk - Share price stability

Non-Executive Chair recently bought €115k worth of stock

Oxford Biomedica Talks to Buy ABL Europe

First half 2023 earnings released: UK£0.50 loss per share (vs UK£0.27 loss in 1H 2022)

Oxford Biomedica plc Provides Revenue Guidance for the Year 2023 and 2024

Oxford Biomedica plc to Report First Half, 2023 Results on Sep 20, 2023

Oxford Biomedica plc Launches TetraVectaTM - the Next Generation Lendediviral Vector System

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Full year 2022 earnings released: UK£0.41 loss per share (vs UK£0.23 profit in FY 2021)

High number of new directors

Oxford Biomedica plc Announces Siyamak Rasty Will Not Be Standing for Re-Election

Oxford Biomedica Appoints Frank Mathias as Board Director

High number of new directors

Kadans Science Partner B.V. agreed to acquire Windrush Court facility from Oxford Biomedica plc (LSE:OXB) for £60 million.

First half 2022 earnings released: EPS: UK£0 (vs UK£0.22 in 1H 2021)

Oxford Biomedica plc Provides Earnings Guidance for the Second Half of 2022

Oxford Biomedica plc to Report First Half, 2022 Results on Sep 15, 2022

Oxford Biomedica plc(LSE:OXB) dropped from FTSE 350 Index (GBP)

Investor sentiment deteriorated over the past week

Oxford Biomedica Notes Announcement That FDA Has Lifted Clinical Hold on Homology Medicines' Phenix Trial

John Dawson Has Steps Down from the Oxford Biomedica Plc's Board of Directors

Full year 2021 earnings released: EPS: UK£0.23 (vs UK£0.078 loss in FY 2020)

High number of new directors

Interim CEO & Chairman recently bought €412k worth of stock

Full year 2021 earnings released: EPS: UK£0.23 (vs UK£0.078 loss in FY 2020)

Oxford Biomedica plc Provides Revenue Guidance for the Year 2022

Oxford Biomedica plc Announces the Appointment of Namrata P Patel as Independent Non-Executive Director

Oxford Biomedica plc to Report Fiscal Year 2021 Results on Apr 20, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc, Annual General Meeting, Mar 08, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc announced that it expects to receive £50.000001 million in funding

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.087 loss in 1H 2020)

Non-Executive Director Andrew John Heath has left the company

Full year 2020 earnings released: UK£0.078 loss per share (vs UK£0.22 loss in FY 2019)

Oxford Biomedica plc Provides Earning Guidance for the Year 2021

Oxford Biomedica plc to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day high: €12.24

Non-Executive Director has left the company

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc(LSE:OXB) dropped from FTSE All-Small Index (GBP)

New 90-day high: €10.39

Independent Non-Executive Director recently sold €430k worth of stock

Oxford Biomedica plc Appoints Sam Rasty as Non-Executive Director

New 90-day high: €9.99

Oxford Biomedica plc and PhoreMost Enters Gene Therapy Collaboration

Oxford Biomedica plc Notes Axovant’S Positive Six-Month Follow-Up from Second Cohort of Sunrise- PD Phase 2 Trial of Axo-Lenti-Pd

First half earnings released

Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica plc

Oxford Biomedica plc to Report First Half, 2020 Results on Sep 17, 2020

New 90-day high - €9.92

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad